John is a business development expert with a strong scientific foundation. He excels at distilling complex scientific and clinical concepts into compelling strategies for groundbreaking strategic partnerships. Driven by the potential of creative collaborations to drive growth, accelerate progress, and bring new medicines to patients, John has led negotiations and launched multiple collaborations totaling over $10b in value. His achievements include deals with Eli Lilly and Novartis (while at Isomorphic Labs), and AstraZeneca, Hansoh Pharma, and Mallinckrodt (in his previous role at Silence Therapeutics).